Literature DB >> 8380161

Deoxyguanosine-resistant leukemia L1210 cells. Loss of specific deoxyribonucleoside kinase activity.

A H Cory1, I A Shibley, J M Chalovich, J G Cory.   

Abstract

A mouse leukemia L1210 cell line was selected for resistance to deoxyguanosine. The deoxyguanosine-resistant cells (dGuo-R) were 126-fold less sensitive to deoxyguanosine than the wild-type cells. The IC50 values for araC and araG were increased, but only 10-12-fold in the dGuo-R cells when compared with the wild-type cells. The dGuo-R cell line showed an increased level of resistance to 2-fluoro-2'-deoxyadenosine and 2-fluoroadenine arabinoside (11-14-fold), but essentially no increase in resistance to deoxyadenosine or adenine arabinoside. Deoxyribonucleoside kinase activity was decreased only slightly (19%) when deoxycytidine was utilized as substrate; when cytosine arabinoside or deoxyguanosine was used as the substrate, the kinase activity in the extracts from the dGuo-R cells was only 10% of the enzyme activity in the extracts from the wild-type cells. The determination of the kinetic parameters, Km and Vmax, indicated that there were marked decreases in the Vmax values for deoxyguanosine and cytosine arabinoside as substrates, but not for deoxycytidine as substrate; the Km values for deoxycytidine and cytosine arabinoside were increased in the extracts from the dGuo-R cells. By use of high-performance liquid chromatography, the kinase activities in the extracts from the wild-type and resistant cells could be resolved. There was the specific loss of kinase activity toward cytosine arabinoside and deoxyguanosine as substrates. These data indicate that the dGuo-R cells have decreased levels of a specific deoxyribonucleoside kinase activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380161      PMCID: PMC1201387     

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Allosteric regulation of calf thymus ribonucleoside diphosphate reductase.

Authors:  S Eriksson; L Thelander; M Akerman
Journal:  Biochemistry       Date:  1979-07-10       Impact factor: 3.162

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Purification of deoxycytidine kinases from two P815 murine neoplasms and their separation from deoxyguanosine kinase.

Authors:  M B Meyers; W Kreis
Journal:  Arch Biochem Biophys       Date:  1976-11       Impact factor: 4.013

4.  Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside.

Authors:  R L Momparler; G A Fischer
Journal:  J Biol Chem       Date:  1968-08-25       Impact factor: 5.157

5.  Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.

Authors:  K Bhalla; R Nayak; S Grant
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

6.  Effects of mutational loss of adenosine kinase and deoxycytidine kinase on deoxyATP accumulation and deoxyadenosine toxicity in cultured CEM human T-lymphoblastoid cells.

Authors:  M S Hershfield; J E Fetter; W C Small; A S Bagnara; S R Williams; B Ullman; D W Martin; D B Wasson; D A Carson
Journal:  J Biol Chem       Date:  1982-06-10       Impact factor: 5.157

7.  Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts.

Authors:  I S Kazmers; B S Mitchell; P E Dadonna; L L Wotring; L B Townsend; W N Kelley
Journal:  Science       Date:  1981-12-04       Impact factor: 47.728

8.  Differences in metabolism and cytotoxicity between 9-beta-D arabinofuranosyladenine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in human leukemic lymphoblasts.

Authors:  L W Dow; D E Bell; L Poulakos; A Fridland
Journal:  Cancer Res       Date:  1980-05       Impact factor: 12.701

9.  Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts.

Authors:  D S Shewach; P E Daddona; E Ashcraft; B S Mitchell
Journal:  Cancer Res       Date:  1985-03       Impact factor: 12.701

10.  Identification of the mechanism of activation of 9-beta-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases.

Authors:  V Verhoef; J Sarup; A Fridland
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

View more
  1 in total

Review 1.  New targets for pyrimidine antimetabolites for the treatment of solid tumours. 2: Deoxycytidine kinase.

Authors:  V W Ruiz van Haperen; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.